

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM648398

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>SEQUENCE:</b>	1		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Baush Health Ireland Limited		05/20/2021	Private Unlimited Company: IRELAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Barclays Bank PLC, as Collateral Agent		
<b>Street Address:</b>	745 Seventh Avenue		
<b>City:</b>	New York		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10019		
<b>Entity Type:</b>	Private Limited Company: UNITED KINGDOM		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90637518	XENAZINE (TETRABENAZINE)	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	800-494-5225		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Stewart Walsh		
<b>Address Line 1:</b>	1025 Connecticut Ave NW, Suite 712		
<b>Address Line 2:</b>	COGENCY GLOBAL Inc.		
<b>Address Line 4:</b>	Washington, D.C. 20036		
<b>ATTORNEY DOCKET NUMBER:</b>	1377712 TM A		
<b>NAME OF SUBMITTER:</b>	Ashley Min Joo Kim		
<b>SIGNATURE:</b>	/Ashley Min Joo Kim/		
<b>DATE SIGNED:</b>	05/20/2021		
<b>Total Attachments: 9</b>			
source=A - Trademarks - Barclays 2021 Q1#page2.tif			
source=A - Trademarks - Barclays 2021 Q1#page3.tif			

OP \$40.00 90637518

source=A - Trademarks - Barclays 2021 Q1#page4.tif  
source=A - Trademarks - Barclays 2021 Q1#page5.tif  
source=A - Trademarks - Barclays 2021 Q1#page6.tif  
source=A - Trademarks - Barclays 2021 Q1#page7.tif  
source=A - Trademarks - Barclays 2021 Q1#page8.tif  
source=A - Trademarks - Barclays 2021 Q1#page9.tif  
source=A - Trademarks - Barclays 2021 Q1#page10.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of May 20, 2021, (this “**Agreement**”), among the entities identified as grantors on the signature pages hereto (collectively, the “**Grantors**”) and Barclays Bank PLC (“**Barclays**”), as collateral agent (in such capacity, the “**Collateral Agent**”) for the Secured Parties.

Reference is made to that certain Third Amended and Restated Pledge and Security Agreement, dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and in effect on the date hereof, the “**Security Agreement**”), among the Loan Parties party thereto and the Collateral Agent. The Lenders (as defined below) have extended credit to the Borrowers subject to the terms and conditions set forth in that certain Fourth Amended and Restated Credit and Guaranty Agreement dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified and in effect on the date hereof, the “**Credit Agreement**”), by and among Bausch Health Companies, Inc. (formerly known as Valeant Pharmaceuticals International, Inc., the “**Parent**”), Bausch Health Americas, Inc. (formerly known as Valeant Pharmaceuticals International, and, together with the Parent, the “**Borrowers**”), certain subsidiaries of the Parent, as subsidiary guarantors, the Lenders from time to time party thereto (the “**Lenders**”), and Barclays, in its capacities as the Swingline Lender and as Administrative Agent for the Lenders. Consistent with the requirements set forth in Sections 4.01 and 5.12 of the Credit Agreement and Section 4.3 of the Security Agreement, the parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement.

SECTION 2. **Grant of Security Interest.** As security for the prompt and complete payment or performance, as the case may be, in full of the Secured Obligations, each Grantor, pursuant to the Security Agreement, did and hereby does pledge, collaterally assign, mortgage, transfer and grant to the Collateral Agent, its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties, a continuing security interest in all of its right, title or interest in, to or under all of the following assets, whether now owned or at any time hereafter acquired by or arising in favor of such Grantor and regardless of where located (the Trademark Collateral, Patent Collateral and Copyright Collateral, each as defined below, collectively, the “**IP Collateral**”):

A. The “**Trademark Collateral**”, defined as set forth in paragraphs (1) through (4) directly below:

1. all Trademarks, including those Trademark registrations and registration applications in the United States Patent and Trademark Office listed on Schedule I hereto;
2. all goodwill associated with or symbolized by the Trademarks;
3. the right to sue third parties for past, present and future infringements, dilutions or violations of any Trademark; and
4. all proceeds of and rights associated with the foregoing;

B. The “**Patent Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Patents, including those Patent registrations and pending applications in the United States Patent and Trademark Office listed on Schedule II hereto;

2. the right to sue third parties for past, present and future infringements of any Patent; and
3. all proceeds of and any right associated with the foregoing; and

C. The “**Copyright Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Copyrights, including those Copyright registrations and pending applications for registration in the United States Copyright Office listed on Schedule III;
2. the right to sue third parties for past, present and future infringements of any Copyright, and
3. all proceeds of and rights associated with the foregoing;

Notwithstanding anything to the contrary in (A) through (C) above, this Agreement shall not constitute a grant of a security interest in any Excluded Assets, including any “intent-to-use” Trademark applications prior to the filing and acceptance of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto.

**SECTION 3. Security Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.


**SECTION 4. Governing Law.** This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

**SECTION 5. Counterparts.** This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]

BAUSCH HEALTH IRELAND LIMITED

By:




\_\_\_\_\_  
Name: William N. Woodfield

Title: Director

BAUSCH+LOMB IRELAND LIMITED

By:




\_\_\_\_\_  
Name: William N. Woodfield

Title: Director

SALIX PHARMACEUTICALS, INC.

By:




\_\_\_\_\_  
Name: William N. Woodfield

Title: Vice President, Treasurer

MEDICIS PHARMACEUTICAL CORPORATION

By:




\_\_\_\_\_  
Name: William N. Woodfield

Title: Vice President, Treasurer

BAUSCH & LOMB INCORPORATED

By:




\_\_\_\_\_  
Name: William N. Woodfield

Title: Vice President, Treasurer

SOLTA MEDICAL, INC.

By:




---

Name: William N. Woodfield

Title: Vice President, Treasurer

SALIX PHARMACEUTICALS, LTD

By:



---

Name: William N. Woodfield

Title: Vice President, Treasurer

[Signature Page to IPSA – Barclays]

**TRADEMARK**  
**REEL: 007300 FRAME: 0620**

Accepted and Agreed:

**BARCLAYS BANK PLC,**  
as Collateral Agent

By:

DocuSigned by:  
*Robert Walsh*  
FCDAF84F50AA411...

---

Name: Robert Walsh  
Title: Assistant Vice President

[Signature Page to IPSA – Barclays]

**TRADEMARK**  
**REEL: 007300 FRAME: 0621**

Schedule I - Trademark Collateral Schedule I - Trademark Collateral

Current Owner on TMO Records	Mark Name	Current Application Number	Current Registration Number
Baush Health Ireland Limited	XENAZINE (TETRABENAZINE)	90637518	



**Schedule II – Patent Collateral**

Appl. No.	Publ. No.	Patent No.	Title	Current PTO Owner
17/158562			ULTRASONIC NEEDLES AND TRANSDUCER ASSEMBLIES FORMED OF NON-METAL MATERIALS OR A COMBINATION OF MATERIALS	BAUSCH & LOMB INCORPORATED
63/159881			PACKAGING SOLUTIONS	BAUSCH + LOMB IRELAND LIMITED
63/157130			MOLDS FOR PRODUCTION OF OPHTHALMIC DEVICES	BAUSCH + LOMB IRELAND LIMITED
63/159097			OPHTHALMIC SOLUTIONS	BAUSCH + LOMB IRELAND LIMITED
63/161002			BIOMEDICAL DEVICES	BAUSCH + LOMB IRELAND LIMITED
17/154591			TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS	BAUSCH HEALTH US, LLC
17/177116			LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS	MEDICIS PHARMACEUTICAL CORPORATION
17/197561			METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)	SALIX PHARMACEUTICALS, INC.
63/152457			"27-DESMETHYLRIFAXIMIN AND USES THEREOF	SALIX PHARMACEUTICALS, LTD
63/158784			METHODS OF USING SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY	BAUSCH HEALTH IRELAND LIMITED

Appl. No.	Publ. No.	Patent No.	Title	Current PTO Owner
63/157258			METHODS OF USING RIFAMYCIN SV FOR THE TREATMENT OF SICKLE CELL DISEASE	BAUSCH HEALTH IRELAND LIMITED
17/162482			TISSUE TREATMENT APPARATUS AND SYSTEMS WITH PAIN MITIGATION AND METHODS FOR MITIGATING PAIN DURING TISSUE TREATMENTS	SOLTA MEDICAL, INC.
17/184256			AGONISTS OF GUANYLATE CYCLASE AND THEIR USES	BAUSCH HEALTH IRELAND LIMITED
17/022398	20210087384		GRAFTED POLYMER AND USE THEREOF	BAUSCH HEALTH IRELAND LIMITED

None.

**Schedule III - Copyright Collateral**